Endocrine Abstracts

JOINT3353

Background: This study assesses the impact of Therapeutic Patient Education (TPE) on quality of life in patients with chronic hypoparathyroidism.

Methods: We extracted Quality of Life results (assessed by SF36) on our cohort of patients with hypoparathyroidism (post-surgery or genetic), divided into three groups: (1) Standard Care (Control, n = 10), (2) included in our program of Therapeutic Patient Education (TPE, 6 online sessions co-animated with a patient expert and our referent center, n = 28), and (3) TPE + Teriparatide initiated before TPE (TPE + Teriparatide, n = 11). SF36 questionnaires were completed by the patients at Baseline (before TPE), 3 and 6 months later. Kruskal-Wallis tests were performed to assess group comparability at baseline and to analyze score evolution over time. A post-hoc Mann-Whitney test was applied to identify specific inter-group differences.

Results: Kruskal-Wallis tests indicated significant baseline differences in Physical Functioning (P = 0.0058), Role Physical (P = 0.0013), Role Emotional (P = 0.0392), Energy/Fatigue (P = 0.0327), and General Health Perception (P = 0.0058), indicating that groups were not comparable at baseline. At 3 months, no significant differences in score evolution were found among groups. At 6 months, Physical Functioning (P = 0.0101), Social Functioning (P = 0.0023), Pain (P = 0.0043), and General Health Perception (P = 0.0039) were significantly different between groups. The TPE and the TPE + Teriparatide groups showed significant improvement in Social Functioning compared to the Control group (P = 0.0017 and P = 0.0077, respectively). No significant difference was found between the TPE and TPE + Teriparatide groups. Regarding pain, both the TPE (P = 0.0075) and TPE + Teriparatide (P = 0.0070) groups showed significant improvement compared to the Control group.

Conclusions: SF-36 scores were significantly more impaired in the TPE and TPE + Teriparatide groups compared to the Control group, which is consistent with the fact that these treatments are preferentially targeted at more severe patients. Our findings suggest that TPE significantly improves social functioning and pain perception compared to standard care. The absence of a difference between TPE and TPE + Teriparatide indicates that TPE alone may provide substantial benefits. These results highlight the potential of TPE as a valuable intervention for enhancing the quality of life in patients with chronic hypoparathyroidism. The key role of patient support networks and the long-term effects of TPE should be further evaluated.